Infant Bacterial Therapeutics Stock Cash And Equivalents
IBT-B Stock | SEK 59.00 9.00 18.00% |
Infant Bacterial Therapeutics fundamentals help investors to digest information that contributes to Infant Bacterial's financial success or failures. It also enables traders to predict the movement of Infant Stock. The fundamental analysis module provides a way to measure Infant Bacterial's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Infant Bacterial stock.
Infant |
Infant Bacterial Therapeutics Company Cash And Equivalents Analysis
Infant Bacterial's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Infant Bacterial Cash And Equivalents | 386.75 M |
Most of Infant Bacterial's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infant Bacterial Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition |
In accordance with the recently published financial statements, Infant Bacterial Therapeutics has 386.75 M in Cash And Equivalents. This is 52.89% lower than that of the Healthcare sector and 13.5% lower than that of the Biotechnology industry. The cash and equivalents for all Sweden stocks is 85.69% higher than that of the company.
Infant Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Infant Bacterial's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Infant Bacterial could also be used in its relative valuation, which is a method of valuing Infant Bacterial by comparing valuation metrics of similar companies.Infant Bacterial is currently under evaluation in cash and equivalents category among its peers.
Infant Fundamentals
Return On Equity | -0.18 | |||
Return On Asset | -0.11 | |||
Current Valuation | 271.56 M | |||
Shares Outstanding | 10.85 M | |||
Shares Owned By Insiders | 7.23 % | |||
Shares Owned By Institutions | 33.28 % | |||
Price To Earning | (18.41) X | |||
Price To Book | 1.72 X | |||
Price To Sales | 8,324 X | |||
Gross Profit | 12 K | |||
EBITDA | (43.76 M) | |||
Net Income | (44.99 M) | |||
Cash And Equivalents | 386.75 M | |||
Cash Per Share | 48.15 X | |||
Current Ratio | 109.37 X | |||
Book Value Per Share | 29.55 X | |||
Cash Flow From Operations | (55.62 M) | |||
Earnings Per Share | (5.76) X | |||
Target Price | 300.0 | |||
Beta | 1.01 | |||
Market Capitalization | 560.25 M | |||
Total Asset | 408.48 M | |||
Net Asset | 408.48 M |
About Infant Bacterial Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Infant Bacterial Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infant Bacterial using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infant Bacterial Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.